Somatic activation of oncogenic Kras in hematopoietic cells initiates a rapidly fatal myeloproliferative disorder.
about
ASXL1 mutations promote myeloid transformation through loss of PRC2-mediated gene repressionDido gene expression alterations are implicated in the induction of hematological myeloid neoplasmsDefective erythroid differentiation in miR-451 mutant mice mediated by 14-3-3zetaManipulation of DNA Repair Proficiency in Mouse Models of Colorectal CancerEngineering mouse models with myelodysplastic syndrome human candidate genes; how relevant are they?Juvenile myelomonocytic leukemia: molecular pathogenesis informs current approaches to therapy and hematopoietic cell transplantationStrategies to achieve conditional gene mutation in miceK-ras/PI3K-Akt signaling is essential for zebrafish hematopoiesis and angiogenesisOncogenic Kras initiates leukemia in hematopoietic stem cellsRAS oncogenes: weaving a tumorigenic webRAS diseases in childrenDevelopmental and species-divergent globin switching are driven by BCL11AOncogenic Kras expression in postmitotic neurons leads to S100A8-S100A9 protein overexpression and gliosisKnock-in of an internal tandem duplication mutation into murine FLT3 confers myeloproliferative disease in a mouse modelRal is both necessary and sufficient for the inhibition of myeloid differentiation mediated by RasGenome profiling of chronic myelomonocytic leukemia: frequent alterations of RAS and RUNX1 genes.Oncogenic RAS enables DNA damage- and p53-dependent differentiation of acute myeloid leukemia cells in response to chemotherapy.Combined MEK and JAK inhibition abrogates murine myeloproliferative neoplasm.Ras activation of Erk restores impaired tonic BCR signaling and rescues immature B cell differentiation.Mutant Ikzf1, KrasG12D, and Notch1 cooperate in T lineage leukemogenesis and modulate responses to targeted agents.Inhibition of the Gab2/PI3K/mTOR signaling ameliorates myeloid malignancy caused by Ptpn11 (Shp2) gain-of-function mutations.Ras oncogene-independent activation of RALB signaling is a targetable mechanism of escape from NRAS(V12) oncogene addiction in acute myeloid leukemia.Prognostic impact of RAS mutations in patients with myelodysplastic syndrome.Use of chromosome engineering to model a segmental deletion of chromosome band 7q22 found in myeloid malignancies.p53 loss promotes acute myeloid leukemia by enabling aberrant self-renewal.Oncogenic Nras has bimodal effects on stem cells that sustainably increase competitiveness.Identification of K-ras as the major regulator for cytokine-dependent Akt activation in erythroid progenitors in vivo.Constitutive MAP kinase activation in hematopoietic stem cells induces a myeloproliferative disorder.Germline CBL mutations cause developmental abnormalities and predispose to juvenile myelomonocytic leukemia.Somatic KRAS mutations associated with a human nonmalignant syndrome of autoimmunity and abnormal leukocyte homeostasisSTAT3 supports experimental K-RasG12D-induced murine myeloproliferative neoplasms dependent on serine phosphorylation.A germline gain-of-function mutation in Ptpn11 (Shp-2) phosphatase induces myeloproliferative disease by aberrant activation of hematopoietic stem cells.BRAF kinase domain mutations are present in a subset of chronic myelomonocytic leukemia with wild-type RAS.Induction of histiocytic sarcoma in mouse skeletal muscle.Endogenous oncogenic Nras mutation promotes aberrant GM-CSF signaling in granulocytic/monocytic precursors in a murine model of chronic myelomonocytic leukemiaLyn- and PLC-beta3-dependent regulation of SHP-1 phosphorylation controls Stat5 activity and myelomonocytic leukemia-like disease.Neuronal NF1/RAS regulation of cyclic AMP requires atypical PKC activation.K-RasV14I recapitulates Noonan syndrome in mice.Hematopoiesis and leukemogenesis in mice expressing oncogenic NrasG12D from the endogenous locus.Combining ATR suppression with oncogenic Ras synergistically increases genomic instability, causing synthetic lethality or tumorigenesis in a dosage-dependent manner.
P2860
Q24296658-3655E208-06C8-4B37-B908-3DE90CF36865Q24530021-970E66FC-4DA5-4C5F-BA89-DA7929E031CFQ24600228-118E3E22-A002-4B22-B560-E7436C87356DQ26740310-6023110E-8D9E-4922-B3D4-250CAE439697Q26828777-171F63F8-910D-4F61-A8D9-ECA56E143241Q26851000-79A98961-94F5-4E66-A2EB-ED21CF06A371Q27023444-E3F5CFD1-8EEA-4301-9392-B05CE18C6AF3Q27300812-471FAB16-C7C7-4912-AB68-D2B37CEE410EQ27331698-A1FC0966-4453-496A-9A93-405C58E119B4Q28250360-BA1C5642-EA50-4593-8459-5EE7D099CBF8Q28252058-ED83B261-EC94-4BF0-8A12-EABE868F828DQ28506497-FC13C49B-09DF-45CF-8EFB-2A97C96CAFB2Q28589373-27155499-94C2-41D0-8591-8109AB5944C2Q28590872-2F0E2DA0-95F2-4E9B-AC67-F4F5D9CE3897Q33241589-5E6D83A5-1102-4266-A7E9-3B94228E0A21Q33377270-FABB4AAE-DD07-4D8F-AE65-167DBCD1E74FQ33515031-1C5C6FF2-5FF6-4A68-877A-7A79E0351B5CQ33685977-89A495EB-B8C8-4CD4-9099-2623B32BF0A6Q33730095-95E44060-660C-45EC-A4C8-EF82565D1C56Q33739961-5FB1A9F1-D7E1-4DD4-8257-DAA2D71F8E69Q33774488-7DE45B2F-5DDC-4DB3-A820-A094D975E55FQ33779805-D3DDEEAB-AA84-4A74-921B-39CF1EBF69ADQ33871210-41C99C5A-4521-4F3E-9FCD-1BE996E8D44BQ33896721-A322A7F0-A876-4A27-8C54-E1FE9E677B6EQ33953631-D847B6E0-20A3-45E2-BF70-70EF2E6BDE68Q34027499-3176E0A6-AE75-45E7-B3E8-6A9095BE94F2Q34078624-345D4C24-FB2A-4AD6-A5C4-B8851E05E02BQ34099193-A851F3DA-46CB-4C54-A21D-AC47EEAB0AE9Q34130332-8926E0A4-5B08-4CCC-BD44-F347BBEB7AD9Q34149957-AC155CB9-3EA3-4C9B-B6A4-F2149248E815Q34284326-8AD3ABE4-FBB0-4BC5-830B-862B3CB20717Q34310556-2A65DAF9-36B6-4462-82E9-504B7BA482C1Q34393208-3D66523C-EE1B-4A24-A701-CE91BEFA7273Q34406138-828014F5-3EAB-4ED3-8C40-BF17AFE355BFQ34541588-5764AB3A-EA94-40E0-A7F9-E5D1F4EB5755Q34541593-2706032F-2F9B-4F6F-8DC9-B898481C94E3Q34575699-C463423E-6219-4437-8C4B-F735E857EA95Q34581270-8CBB1AA9-3E2C-4E56-94AC-E3BF6EFDD41BQ34667782-D7ADD41C-1865-405C-B084-0732ED4CDFB7Q34676703-A192F640-5173-44F8-BE8E-A62D3A112625
P2860
Somatic activation of oncogenic Kras in hematopoietic cells initiates a rapidly fatal myeloproliferative disorder.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
2003年论文
@zh
2003年论文
@zh-cn
name
Somatic activation of oncogeni ...... l myeloproliferative disorder.
@ast
Somatic activation of oncogeni ...... l myeloproliferative disorder.
@en
type
label
Somatic activation of oncogeni ...... l myeloproliferative disorder.
@ast
Somatic activation of oncogeni ...... l myeloproliferative disorder.
@en
prefLabel
Somatic activation of oncogeni ...... l myeloproliferative disorder.
@ast
Somatic activation of oncogeni ...... l myeloproliferative disorder.
@en
P2093
P2860
P356
P1476
Somatic activation of oncogeni ...... l myeloproliferative disorder.
@en
P2093
Benjamin S Braun
Jacob Rozmus
Kevin M Shannon
Michelle M Le Beau
Namie Kong
Scott C Kogan
Tyler E Jacks
P2860
P304
P356
10.1073/PNAS.0307203101
P407
P577
2003-12-29T00:00:00Z